AKBA FY 2025 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$236M+47.5% YoY

Gross Profit

$197M83.3% margin

Operating Income

$23M9.9% margin

Net Income

-$5M-2.3% margin

EPS (Diluted)

$-0.02

Cash Flow

Operating Cash Flow

$68M

Free Cash Flow

$68M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$377M

Total Liabilities

$344M

Stockholders' Equity

$33M

Cash & Equivalents

$185M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$236M	$160M	+47.5%
Gross Profit	$197M	$97M	+102.8%
Operating Income	$23M	-$50M	+146.6%
Net Income	-$5M	-$69M	+92.3%